QUALITATIVE RESEARCH IN HAEMOPHILIA A: EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

被引：1
|
作者：
Lambert, T. [1 ]
Rothschild, C. [2 ]
Baillon, N. [3 ]
Gaudin, H. [4 ]
Acquadro, M. [5 ]
Arnould, B. [5 ]
Lambert, J. [5 ]
Negrier, C. [6 ]
机构：
[1] Hop Bicetre, AP HP, Le Kremlin Bicetre, France
[2] Hop Necker Enfants Malad, Paris, France
[3] Roche SAS, Boulogne, France
[4] Chugai Pharma France, Puteaux La Defense, France
[5] Mapi, Lyon, France
[6] CHU Lyon, HCL, Bron, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2921
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY223
引用
收藏
页码：S474 / S474
页数：1
相关论文
共 50 条
  • [41] Real-world data on the use of emicizumab in patients with haemophilia A with and without inhibitors in Singapore
    Lee, Ming Wei
    Cheong, May Anne
    Ng, Heng Joo
    Tien, Sim Leng
    Lam, Joyce Ching Mei
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, 52 (11) : 580 - 589
  • [42] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
    Cortesi, P. A.
    Castaman, G.
    Trifiro, G.
    Ferrario, M.
    Improta, G.
    Mazzaglia, G.
    Molinari, A. C.
    Mantovani, L. G.
    VALUE IN HEALTH, 2019, 22 : S845 - S845
  • [43] Real-world experience with the use of emicizumab in paediatric haemophilia A patients with and without inhibitors
    Lam, Joyce Ching Mei
    Lim, Chiew Ying
    Kadir, Nur Insyirah Abdul
    HAEMOPHILIA, 2022, 28 : 50 - 51
  • [44] Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
    Collins, P. W.
    Liesner, R.
    Makris, M.
    Talks, K.
    Chowdary, P.
    Chalmers, E.
    Hall, G.
    Riddell, A.
    Percy, C. L.
    Hay, C. R.
    Hart, D. P.
    HAEMOPHILIA, 2018, 24 (03) : 344 - 347
  • [45] Use of emicizumab in patients with haemophilia A: Experience from a treatment centre in, Ghana, West Africa
    Dwuma-Badu, Diana
    Segbefia, Catherine
    Amegan-Aho, Kokou Hefoume
    Peprah, Albert
    Degbotse, Aimee
    Bainson, Samuel
    HAEMOPHILIA, 2024, 30 : 151 - 151
  • [46] Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein, Katharina
    Le Quellec, Sandra
    Klamroth, Robert
    Batorova, Angelika
    Holme, Pal Andre
    Jimenez-Yuste, Victor
    Astermark, Jan
    HAEMOPHILIA, 2022, 28 (02) : 215 - 222
  • [47] The thrombin generation assay as a method for monitoring haemophilia A patients using emicizumab and FVIII treatment
    Monard, A.
    Urlings, E.
    van de Berg, T.
    Hellenbrand, D.
    van Oerle, R.
    Beckers, E.
    Heubel-Moenen, F.
    Henskens, Y.
    HAEMOPHILIA, 2024, 30 : 41 - 41
  • [48] Real experience of prophylaxis with emicizumab in patients with congenital haemophilia A with and without FVIII inhibitors in the HCUVA
    Heredia Cano, Angela
    Garcia Candel, Faustino
    Sanchez Villalobos, Maria
    Poveda Garcia, Andrea
    Torchia Esteban, Marcos
    Ruiz Ruiz, Estela
    Sanchez Salas, Jose Antonio
    Navarro Almenzar, Begona
    Caracena Lopez, Sara
    Perez Laencina, Marta
    Blazquez Soto, Juan Antonio
    HAEMOPHILIA, 2024, 30 : 31 - 32
  • [49] QUALITATIVE RESEARCH EVALUATING PATIENT PREFERENCE FOR HAEMOPHILIA THERAPY
    Miesbach, W.
    Valentino, L. A.
    Noone, D.
    Forsyth, K.
    Bullinger, M.
    Dashiell-Aje, E.
    Newman, V.
    Hawes, C.
    Hawley, S.
    Lewis, H. B.
    Latibeaudiere-Gardner, D.
    Quinn, J.
    HAEMOPHILIA, 2022, 28 : 83 - 83
  • [50] Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
    Pfrepper, Christian
    Klamroth, Robert
    Ettingshausen, Carmen Escuriola
    Petros, Sirak
    Siegemund, Annelie
    Siegemund, Thomas
    HAEMOPHILIA, 2024, 30 (02) : 545 - 553
12345